Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer

Ann Oncol. 1992 Feb;3(2):165-6. doi: 10.1093/oxfordjournals.annonc.a058135.

Abstract

Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4%) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Female
  • Humans
  • Middle Aged
  • Mitomycin / administration & dosage
  • Mitoxantrone / administration & dosage

Substances

  • Mitomycin
  • Mitoxantrone